Reviewing CVR Medical (OTCMKTS:CRRVF) & Lyra Therapeutics (NASDAQ:LYRA)

CVR Medical (OTCMKTS:CRRVF) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares CVR Medical and Lyra Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CVR Medical	N/A	N/A	N/A
Lyra Therapeutics	-5,570.88%	-102.22%	-57.77%

Earnings & Valuation

This table compares CVR Medical and Lyra Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVR Medical	N/A	N/A	-$1.82 million	N/A	N/A
Lyra Therapeutics	$1.82 million	9.80	-$62.68 million	($1.58)	-0.17

CVR Medical has higher earnings, but lower revenue than Lyra Therapeutics.

Analyst Recommendations

This is a summary of current ratings and target prices for CVR Medical and Lyra Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVR Medical	0	0	0	0	N/A
Lyra Therapeutics	1	4	1	0	2.00

Lyra Therapeutics has a consensus target price of $4.50, indicating a potential upside of 1,550.77%.

Insider & Institutional Ownership

95.6% of Lyra Therapeutics shares are owned by institutional investors. 4.7% of Lyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

About CVR Medical

CVR Medical Corp., a healthcare company, engages in the research and development of subsonic, infrasonic, and low frequency sound wave analysis technology for the healthcare sector. The company provides carotid stenotic scan device, a diagnostic tool to detect and measure carotid arterial stenosis. It offers its products for patients, payors, and healthcare providers. CVR Medical Corp. was incorporated in 1980 and is headquartered in North Vancouver, Canada.

About Lyra Therapeutics

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.